A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low‐dose liraglutide in otherwise healthy men with overweight or obesity
Year: 2024
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Diabetes Obesity and Metabolism
DOI: 10.1111/dom.15984
Institutions: Boehringer Ingelheim (Germany), Clinical Research Services
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Boehringer Ingelheim
OpenAlex ID: W4403192811